Bertelsen Mette, Rosenberg Thomas, Larsen Michael
Øjenklinikken, Kennedy Centret, Gammel Landevej 7, Glostrup.
Ugeskr Laeger. 2013 Sep 2;175(36):2038-42.
Ongoing clinical trials are targeting several previously intractable hereditary causes of blindness of congenital, childhood or early adulthood onset, mainly in the optic nerve and retina. The intended stage of initiation of the new therapeutic approaches ranges from neonatal life and a structurally intact retinal tissue to adult life with a complete loss of photoreceptors. It must be assumed that some of the trials will succeed in producing new therapies and action must be taken to refine and accelerate diagnostics and to preserve therapeutic potential in blind people.
正在进行的临床试验针对几种先前难以治疗的先天性、儿童期或成年早期失明的遗传性病因，主要涉及视神经和视网膜。新治疗方法的预期起始阶段涵盖从新生儿期和结构完整的视网膜组织到光感受器完全丧失的成年期。必须假定一些试验将成功研发出新疗法，并且必须采取行动完善和加速诊断，并保留盲人的治疗潜力。
